Natalie Gross Selected Research

Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa)

1/2022	Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.
1/2021	Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natalie Gross Research Topics

Disease

2	Inflammation (Inflammations) 10/2023 - 01/2022
2	Bullous Pemphigoid (Pemphigoid) 01/2022 - 01/2022
2	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 01/2022 - 01/2021
1	Dermatitis 10/2023
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2023
1	Skin Diseases (Skin Disease) 01/2021

Drug/Important Bio-Agent (IBA)

2	Phosphotransferases (Kinase)IBA 01/2022 - 01/2022
2	AutoantibodiesIBA 01/2022 - 01/2021
1	IntegrinsIBA 10/2023
1	Imiquimod (Aldara)FDA LinkGeneric 10/2023
1	1-amino-3-imino-N,N'-propene diacetateIBA 10/2023
1	Therapeutic UsesIBA 01/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	IgG Receptors (Fc gamma RI)IBA 01/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	parsaclisibIBA 01/2022
1	Collagen Type VIIIBA 01/2021
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2021
1	TGX 221IBA 01/2021

Therapy/Procedure

1	Therapeutics 10/2023